Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital ...

RBC Capital lowered its price target on Vertex Pharmaceuticals (NASDAQ: VRTX) to $420 from $423 on Monday, while maintaining a Sector Perform rating on the stock.The biotech giant, currently ...

The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company’s next-generation cystic fibrosis treatment, Alyftrek. RBC Capital remains ...

Erste Group downgraded Vertex’s stock from Buy to Hold, citing concerns over high inventory and receivables ratios, despite the potential sales boost from the cystic fibrosis treatment ALYFTREK.

During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK ...

The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company’s next-generation cystic fibrosis treatment, Alyftrek. RBC Capital remains ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average ...

After seeing the impact of my sister’s cystic fibrosis throughout my childhood, my late CF diagnosis, while difficult, has brought healing, strength, and a renewed sense of purpose to my life.